Entero Therapeutics, Inc. (NASDAQ:GRDX) Shares Shorted: Short Interest Down 69.3% in October

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the recipient of a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 30,489 shares, a drop of 69.3% from the October 15th total of 99,241 shares. Based on an average daily volume of 116,642 shares, the short-interest ratio is presently 0.3 days. Approximately 0.4% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Entero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th.

Entero Therapeutics Stock Performance

GRDX stock traded down $1.61 during midday trading on Friday, hitting $3.81. 382,897 shares of the stock were exchanged, compared to its average volume of 116,103. The stock’s 50-day moving average price is $4.25 and its 200-day moving average price is $3.62. The stock has a market cap of $27.19 million, a price-to-earnings ratio of -2.00 and a beta of 1.67. Entero Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $6.93.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for gastrointestinal diseases. The company’s research programs are designed to address conditions involving intestinal inflammation, gluten intolerance and digestive enzyme deficiencies. Its pipeline has included latiglutenase, an oral enzyme therapy being developed for celiac disease, as well as niclosamide-based therapies for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.